• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Pulmatrix doses first patient in Ph1 Pulmazole trial

February 12, 2018 By Sarah Faulkner

PulmatrixPulmatrix (NSDQ:PULM) said today that the first patient was treated in a first-in-human study of Pulmazole – an inhaled formulation of the anti-fungal drug, itraconazole.

The Lexington, Mass.-based company is evaluating its iSperse formulation of the drug as a treatment for asthma patients who have developed allergic bronchopulmonary aspergillosis.

Patients with ABPA are usually given oral itraconazole as an adjunctive treatment to corticosteroids, but the drug is limited thanks to its poor bioavailability and variable pharmacokinetics, according to Pulmatrix. The company hopes that by delivering itraconazole directly to the lung, it can improve upon the drug’s safety and efficacy profile.

The Phase I/Ib study plans to enroll healthy participants and patients with mild to moderate asthma. In the single ascending dose and multiple ascending dose arms of the trial, which are slated to include up to 42 people, Pulmatrix will assess Pulmazole’s safety, tolerability and pharmacokinetics. In a 16-person crossover cohort, the company hopes to conduct pharmacokinetic analyses in patients given a single dose of oral itraconazole or inhaled itraconazole.

“Dosing our first subject with Pulmazole and entering the clinic represents a major milestone for this program,” chief medical officer Dr. Jim Roach said in prepared remarks.

“In addition to generating the requisite safety and tolerability data from this study to advance dosing of Pulmazole into asthmatic patients with ABPA, we anticipate that the collective pharmacokinetic data obtained in Phase 1 will further corroborate the key PK preclinical findings reported last week at the 8th Advances Against Aspergillosis Conference in Lisbon, Portugal – namely, that Pulmazole can provide higher lung exposure and lower systemic exposure than oral Sporanox.”

Top-line results from the study will be available later this year, Pulmatrix reported.

“The initiation of our Pulmazole clinical trial is important validation of our iSperse dry powder technology as the second program to advance into the clinic along with PUR0200,” CEO Robert Clarke added. “We look forward to advancing Pulmazole and our iSperse pipeline to improve the treatment approaches for patients with unmet medical needs.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Pulmatrix Inc.

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS